Recruiting
Phase 1

ASP2138 with Chemotherapy

Sponsor:

Astellas Pharma Global Development, Inc.

Code:

NCT07024615

Conditions

Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ASP2138

Oxaliplatin

Leucovorin

5-FU

Irinotecan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-29. This information was provided to ClinicalTrials.gov by Astellas Pharma Global Development, Inc. on 2026-03-13.